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Abstract
 Although nausea and vomiting are very common in pregnancy,Background:
their pathogenesis is poorly understood. We tested the hypothesis that
circulating growth and differentiation factor 15 (GDF15) concentrations in early
pregnancy, whose gene is implicated in hyperemesis gravidarum, are
associated with nausea and vomiting.
Blood samples for the measurement of GDF15 and human chorionicMethods: 
gonadotrophin (hCG) concentrations were obtained early in the second
trimester (median 15.1 (interquartile range 14.4-15.7) weeks) of pregnancy
from 791 women from the Cambridge Baby Growth Study, a prospective
pregnancy and birth cohort. During each trimester participants completed a
questionnaire which included questions about nausea, vomiting and antiemetic
use. Associations with pre-pregnancy body mass indexes (BMI) were validated
in 231 pregnant NIPTeR Study participants.
 Circulating GDF15 concentrations were higher in women reportingResults:
vomiting in the second trimester than in women reporting no pregnancy nausea
or vomiting: 11,581 (10,977-12,219) (n=175) vs. 10,593 (10,066-11,147)
(n=193) pg/mL, p=0.02). In women who took antiemetic drugs during
pregnancy (n=11) the GDF15 levels were also raised 13,157 (10,558-16,394)
pg/mL (p =0.04). Serum GFD15 concentrations were strongly positively
correlated with hCG levels but were inversely correlated with maternal BMIs, a
finding replicated in the NIPTeR Study.
Week 15 serum GDF15 concentrations are positively associatedConclusions: 
with second trimester vomiting and maternal antiemetic use in pregnancy.
Given GDF15’s site of action in the chemoreceptor trigger zone of the
brainstem and its genetic associations with hyperemesis gravidarum, these
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 brainstem and its genetic associations with hyperemesis gravidarum, these
data support the concept that GDF15 may be playing a pathogenic role in
pregnancy-associated vomiting.
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Introduction
Nausea and vomiting in pregnancy (NVP) affects 70–90% of all 
pregnant women. The most severe form of NVP, hyperemesis 
gravidarum (HG), leads to maternal dehydration and electrolyte 
imbalance and is the most common cause of hospital admission 
during early pregnancy1. Even though the majority of cases of 
NVP are mild or moderate with little impact upon maternal 
well-being, HG has substantial consequences for the mother’s 
quality of life2, psychological morbidity3, workplace productivity4 
and decreased caloric intake for the mother5,6. Furthermore, 
HG may have potential adverse effects on the developing fetus, 
as indicated by higher likelihood of low birth weight, preterm 
delivery, and small size at birth for gestational age in women 
with HG7. While effective pharmacological interventions 
are available, there are concerns regarding possible fetal 
teratogenicity of some agents8.
The pathogenesis of HG is poorly understood. Primiparity, 
younger maternal age, non-smoking1 and being underweight9–11 
may be risk factors. Reproductive hormones, such as human 
chorionic gonadotropin (hCG), progesterone and estrogen, have 
been implicated due to their rise in concentrations in the mother’s 
circulation contemporaneous with the manifestation of NVP12. 
However nausea and vomiting are not common side-effects of 
such agents when administered in other settings, nor are increases 
in reproductive hormones consistently associated with increased 
HG severity or duration13. A family history of HG leads to a 
3-fold increase in HG among the female offspring14, which has 
led to the hypothesis that it may be genetically driven. Recent 
studies of HG have tentatively implicated rare variants in TSHR, 
which encodes the thyrotropin receptor15, and RYR216, which 
encodes a stress-induced intracellular calcium release chan-
nel in some familial cases. Evolutionary theories have been pro-
posed for NVP as a beneficial strategy to protect the fetus from 
maternal ingestion of noxious substances, particularly during 
the early stages of pregnancy, coinciding with organogenesis, 
when the fetus is most vulnerable12.
Growth and Differentiation Factor 15 (GDF15) signaling 
through its receptor (a heterodimer of proteins coded for by the 
GDNF family receptor α–like (GFRAL) and Rearranged During 
Transfection (RET) genes) has recently been identified to acti-
vate the mammalian chemoreceptor trigger zone of the medulla 
to suppress food intake in mice17–20 and primates21. As such it 
therefore represents a potential mechanism for the aversion to 
foods and eating behaviors during periods of stress, sickness or 
high vulnerability to external toxins12. In the non-pregnant state 
GDF15 is expressed at low levels in many tissues. In preg-
nancy, GDF15 is highly expressed in the placenta from early 
time points. In standard pregnancies circulating levels rise 
rapidly in maternal blood during the first trimester of preg-
nancy and remain elevated until delivery22. A genome wide 
association study has recently shown that variants in and 
around the GDF15 locus are strongly associated with the risk 
of HG in pregnancy23.
To explore the hypothesis that NVP might relate to circulat-
ing GDF15 levels, we measured serum GDF15 in Cambridge 
Baby Growth Study samples obtained from women who 
had been prospectively followed throughout their pregnan-
cies. They had answered questionnaires in each of the three 
trimesters which had incorporated questions regarding nausea, 
vomiting and antiemetic use. As previous research has variably 
implicated hCG in the pathogenesis of NVP24 we exam-
ined the relationships between hCG levels, NVP symptoms 
and GDF15 concentrations in those women in whom these 
measures were available. As there have been reports that low 
pre-pregnancy body mass index (BMI) predisposes to NVP9 we 
also examined the relationship between pre-pregnancy BMI, 
GDF15 levels and NVP.
Methods
Cohort 1: Cambridge Baby Growth Study
The prospective Cambridge Baby Growth Study recruited 2,229 
mothers (and their partners and offspring) attending antenatal 
ultrasound clinics during early pregnancy at the Rosie Mater-
nity Hospital, Cambridge, United Kingdom, between 2001-925. 
All mothers were over 16 years of age. Pre-pregnancy weight 
and height were self-reported. In this cohort, 96.9% of the off-
spring were of white ethnicity, 0.8% were of mixed race, 0.6% 
were black (African or Caribbean), 0.8% were East-Asian, 
and 0.9% were Indo-Asian. Research blood samples, from 
which serum was separated and aliquoted, were collected from 
1,177 (52.8%) mothers at recruitment (median 15.0 weeks, 
interquartile range 1.6 weeks). Around week 14 of pregnancy 
the participants were offered the chance to have routine blood 
taken for the measurement of serum alpha-fetoprotein (AFP), 
hCG and unconjugated estriol (uE3) as the pre-natal screening 
triple test.
Each mother was given a printed questionnaire at recruitment 
to fill in and return after the birth of their child26. The par-
ticipants were encouraged to fill their questionnaire in as their 
pregnancy progressed. It included boxes to tick if the partici-
pants had experienced NVP during pregnancy27. If either the 
nausea or vomiting boxes was ticked there were further boxes 
to complete concerning the timing (i.e. week(s) of pregnancy) 
when the nausea or vomiting was experienced. An additional 
question asked “Have you taken any medicine during this preg-
nancy?” and a table was provided for positive responses with 
the following headings: “Name”, “Disease”, “Daily Dose”, 
“No. of Days” and “Gestational Week(s)”. A total of 1,238 
women (54.6%) returned a questionnaire. Of these, only 3 
self-reported that they had HG and a further 17 reported 
treatment with an antiemetic agent: cyclizine (n=7), promet-
hazine (n=5), prochlorperazine (n=4), metoclopramide (n=2), 
domperidone (n=2), prednisolone (n=2), chlorphenamine (n=1), 
ondansetron (n=1), chlorpromazine (n=1) and unknown (n=1). 
The timing of NVP was categorized into trimesters (first: up 
to gestational week 12; second: 13 to 27 weeks; third: 28+ weeks).
The current analysis was based on 791 women in the 
Cambridge Baby Growth Study who had an available serum 
sample collected between gestational age 12 and 18 weeks and 
returned a completed questionnaire26,27. Of these there were only 
11 women who reported taking antiemetics during pregnancy. 
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These women were representative of the whole cohort by having 
similar maternal pre-pregnancy BMIs, parities and offspring birth 
weights (adjusted for standard confounders) to those women 
who did not return a pregnancy questionnaire (Supplementary 
Table 1).
Cohort 2: NIPTeR Study
The Non-Invasive Prenatal RNA profiling in pregnancy (NIPTeR) 
study was set up to research the early detection of preeclamp-
sia before symptoms emerge. Included were pregnant women 
of at least 18 years old at their first antenatal visit. Enrolment 
took place between September 2015 and November 2017 at 
the Academic Medical Center, Amsterdam, The Netherlands. 
Antiemetic use, history of hospital admissions for HG, and 
pre-pregnancy weight and height were retrieved from the medi-
cal charts. In addition to the routine blood samples, a blood 
sample for the NIPTeR Study was taken. Within 6 hours of 
blood collection plasma was isolated by a 2-step protocol: 
first a low speed platelet-rich plasma separation, followed by a 
general high-speed step for clearance of all cells.
The current analysis was based on data from 231 women whose 
blood was sampled between 10 and 18 weeks of pregnancy who 
did not report developing HG/antiemetic use.
Ethics
The Cambridge Baby Growth Study was approved by the 
Cambridge Research Ethics Committee, Cambridge, United 
Kingdom (LREC 00/325). All procedures followed were in 
accordance with Good Clinical Practice guidelines. Written 
informed consent was obtained from all the study participants. 
The NIPTeR study was approved by the Academic Medical 
Center ethics committee (reference 2015_072) and all 
participating women provided written informed consent.
Assays
GDF15 concentrations were measured in serum (Cambridge 
Baby Growth Study) and EDTA plasma (NIPTeR) using an 
in-house Meso Scale Discovery electrochemiluminescence 
immunoassay (Meso Scale Diagnostics, Rockville, Maryland, 
U.S.A.) developed using antibodies from R & D Systems 
Quantikine reagents (BioTechne Ltd., Abingdon, U.K.). The 
sensitivity of this assay was 3 pg/mL and the working range 
went up to 32,000 pg/mL. Batch-to-batch variability was 9.8% 
at 352 pg/mL, 8.1% at 1490 pg/mL and 7.8% at 6667 pg/mL. 
Pre-natal screening assays were performed using routine 
AutoDELFIA time-resolved fluoroimmunoassays (PerkinElmer 
Life Sciences, Wallac Oy, Turku) and the results were expressed 
as multiples of the median (MOM)28.
Statistical analysis
Women in the Cambridge Baby Growth Study were catego-
rized into one of three groups: vomiting (independent of whether 
they reported having experienced nausea or not); nausea but no 
vomiting; and no nausea or vomiting27. The primary outcome 
was vomiting during the second trimester, as this coincided with 
the timing of maternal serum sampling. These were compared 
to concentrations in women who reported no nausea or vomit-
ing. Maternal pre-pregnancy BMI was calculated dividing body 
weight prior to pregnancy by height-squared. NIPTeR Study 
samples were used to validate the relationship between GDF15 
and BMI.
Serum GDF15 concentrations were natural logarithm- 
transformed to achieve a normal distribution and were consid-
ered as the dependent variable in linear regression models with 
adjustment for gestational age at serum sample collection. Where 
the relationship with adjusted log-transformed GDF15 concen-
trations did not appear to be linear, data were transformed to 
approximate linearity prior to analysis (e.g. the reciprocal BMI 
was used). Statistical analyses were performed using Stata 
13.1 (StataCorp LP, College Station, Texas, U.S.A.). P<0.05 
was considered to indicate statistical significance.
Results
Maternal nausea and vomiting in pregnancy
37.7% (n=298) of the Cambridge Baby Growth Study women 
reported vomiting during any trimester of pregnancy. A 
further 37.9% (n=300) reported nausea but no vomiting, and 
only 24.4% (n=193) of the Cambridge Baby Growth Study 
women reported no nausea or vomiting. More women (32.0%, 
n=253) reported vomiting during the first trimester compared to 
22.1% (n=175) in the second trimester, with only 3.8% (n=30) 
in the third trimester. 86.9% and 56.7% of those reporting 
vomiting in the second and third trimesters also reported vomit-
ing during the first trimester, respectively. Women who reported 
vomiting during the second trimester were younger and were 
carrying relatively more female babies than women who 
reported no nausea or vomiting during pregnancy (Table 1), 
but there were no differences in pre-pregnancy BMI.
Maternal GDF15 concentrations
In the Cambridge Baby Growth Study the median GDF15 
concentration was 11,004 pg/mL (range 2,378–34,621) in serum 
samples collected at mean gestational age 15.1 weeks (range 
12.0–18.0). Maternal GDF15 concentrations were not associated 
with gestational age at sampling (linear model with log-
GDF15: P=0.4, standardized β=-0.03). In the NIPTeR Study 
the median GDF15 concentration was 11,014 pg/mL (range 
4,106–37,194, n=233) in plasma samples collected at mean 
gestational age 12.1 weeks (range 10.0–16.1).
Maternal GDF15 concentrations and associations with 
nausea and vomiting in pregnancy
Maternal GDF15 concentrations around week 15 were higher 
in women who reported vomiting in the second trimester of 
pregnancy compared to those who reported no nausea or vomit-
ing during pregnancy (P=0.02; Table 2). This association was 
unaltered by adjustment for gestation at serum sampling or by 
maternal BMI. There was no significant elevation of GDF15 
concentrations in women reporting nausea alone in the second 
trimester or in women reporting nausea or vomiting in the 
first or third trimesters (Supplementary Table 2).
Eleven women (1.4%) took antiemetics, ten of whom reported 
vomiting and one of whom reported nausea without vomiting. 
Their serum GDF15 concentrations were also raised com-
pared to women who reported no nausea or vomiting during 
pregnancy (P=0.04, adjusted for gestation; Table 2).
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Maternal GDF15 concentrations and associations with 
prenatal screening markers
A subset of participants (441) had undergone a 14 week triple 
test at ~14 weeks gestation measuring AFP, estriol and hCG. 
Maternal serum GDF15 concentrations were not associated 
with AFP (standardized β=0.059, P=0.2, n=441). There was 
a weak positive association with unconjugated estriol (stand-
ardized β=0.110, P=0.02, n=440). In contrast there was a 
strong positive association with hCG (Figure 1; standardized 
β=0.436, P=7.2×10-22, n=441). In contrast to the GDF15 data 
however, hCG levels were not significantly higher in women 
reporting vomiting in the second trimester of pregnancy: no 
nausea or vomiting 1.06 (0.96-1.17) (n=119) v. 1.17 (1.04-1.31) 
(n=91) (P=0.2).
Maternal GDF15 concentrations and associations with  
pre-pregnancy BMI
In the Cambridge Baby Growth Study the distribution of the 
relationship of week 15 GDF15 concentrations and maternal 
pre-pregnancy BMI was asymptotic (Figure 2a), with higher 
GDF15 levels being seen exclusively in leaner mothers. 
The data were analyzed using log transformation of GDF15 
levels (Figure 2b) and a highly significant relationship with the 
reciprocal of pre-pregnancy BMI was apparent (standardized 
β=0.266, p=4.1×10-13, n=721).This relationship was replicated 
in the NIPTeR Study (Figure 2c & d; standardized β=0.280, 
p=1.5×10-5, n=231).
Discussion
In this large prospective pregnancy cohort study, maternal 
circulating GDF15 concentrations around week 15 of pregnancy 
were higher in women who reported vomiting in the second 
trimester and were even higher in women who reported tak-
ing antiemetics during pregnancy, compared to those of women 
who reported no nausea or vomiting during pregnancy. The 
results from the women who took antiemetics during pregnancy 
probably reflect the severity of their symptoms rather than their 
treatment. We also found that week 15 GDF15 concentrations 
Table 2. Maternal GDF15 concentrations by self-reported vomiting in the second trimester or antiemetic use 
during pregnancy. This table shows comparisons of circulating maternal GDF15 concentrations around week 15 
of pregnancy in those women who reported nausea alone or vomiting in the second trimester of pregnancy, those 
women who reported taking antiemetics during pregnancy and those women who reported no nausea or vomiting 
in pregnancy in the Cambridge Baby Growth Study. These concentrations were raised in women who reported 
vomiting whether unadjusted or adjusted for gestational age without or without BMI. Adjusted levels were also 
higher in women who took antiemetics during pregnancy. No apparent differences were observed in women who 
reported nausea alone.
Group n Serum GDF15 
Concentration (pg/mL)
Unadjusted Adjusted for 
gestational age
Additionally adjusted 
for maternal BMI
No nausea or vomiting 193 10,593 (10,066-11,147) Ref Ref Ref
Nausea without vomiting 
(second trimester)
325 10,772 (10,328-11,235) P=0.6 P=0.6 P=0.5
Vomiting (second 
trimester)
175 11,581 (10,977-12,219) P=0.02 P=0.02 P=0.02
Antiemetic use (any 
trimester)
11 13,157 (10,558-16,394) P=0.06 P=0.04 P=0.04
Data are geometric means (95% confidence intervals).
Table 1. Clinical characteristics of the women who reported vomiting during the second 
trimester of pregnancy. This table shows comparisons of clinical characteristics between 
those women that reported vomiting during the second trimester of pregnancy and those 
women that reported no nausea or vomiting throughout pregnancy in the Cambridge Baby 
Growth Study. Those women who reported second trimester vomiting were very slightly 
younger and were carrying a higher proportion of female babies. There were no apparent 
differences in BMI, parity or prevalence of twin pregnancies however.
Vomiting (2nd trimester) No nausea or vomiting p-value
n 175 193
Age at delivery (years) 32.8 (32.1-33.5) 33.7 (33.1-34.3) 0.047
BMI (kg/m2) 23.9 (23.2-24.5) 23.9 (23.3-24.6) 1.0
Parity (n primiparous (%)) 84 (48.0%) 109 (56.5%) 0.1
Offspring Sex (n females (%)) 96 (54.9%) 81 (42.28%) 0.02
Twin pregnancies 2 0 0.2
The comparator group are women who reported no nausea or vomiting during pregnancy. Data are 
geometric means (95% confidence intervals) or numbers of participants.
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were related to maternal pre-pregnancy BMIs, with the highest 
circulating GDF15 concentrations found in mothers with the 
lowest BMIs.
To our knowledge, this is the first report relating GDF15 
concentrations to vomiting during pregnancy. Circulating 
GDF15 concentrations rise rapidly in maternal blood during 
early pregnancy and several studies have reportedly substantially 
lower concentrations at around 6–13 weeks gestation in those 
pregnancies that subsequently miscarried29,30. Possible explana-
tions for this highly reproducible phenomenon have included 
the suggestion that maternal circulating GDF15 is a biomarker 
of successful placentation. Alternatively it has been suggested 
that GDF15 may promote fetal viability through an immu-
Figure 1. The relationship between week 15 maternal serum GDF15 concentrations and week 14 hCG MOMs. (a) A scatter plot of 
untransformed GDF15 concentration and hCG MOM data from around weeks 14–15 of pregnancy in the Cambridge Baby Growth Study, 
(b) a scatter plot of logarithmically-transformed data from the same cohort.
Page 6 of 13
Wellcome Open Research 2018, 3:123 Last updated: 03 OCT 2018
nomodulatory action31. However the recent discovery of the 
highly specific expression of the receptor for GDF15 in the 
hindbrain makes this less likely32. Despite that uncertainty, our 
findings provide a possible mechanistic explanation for the 
widely observed associations between NVP and lower rates 
of miscarriage33.
There are at least three possible interpretations of the inverse 
association between serum GDF15 concentrations and maternal 
pre-pregnancy BMI which we found in two independent 
studies. It is possible that those women who develop high levels 
of GDF15 in pregnancy have an intrinsic tendency to be GDF15 
overproducers. Even in the non-pregnant state, given the known 
effects of this hormone on appetite34 this could be directly related 
to their low weight. Such a hypothesis would need to take into 
account the fact that a substantial amount of the GDF15 found 
in maternal blood is likely to be secreted by the trophoblast, 
which is fetally-encoded and only shares ~50% genetic iden-
tity with the mother. An alternative interpretation is that women 
with a low pre-pregnancy BMI are particularly vulnerable to 
the stressful effects of pregnancy. Consistent with this 
GDF15 appears to be overproduced by a variety of tissues in 
response to different stress states, including undernutrition35. 
Finally our findings could be consistent with the idea that 
early placentation is less successful in women with higher 
BMIs. This notion is supported by the fact that there is a 
graded increase in pregnancy loss with increasing maternal 
BMI36, as well as an increase in maternal placental syndromes, 
including preeclampsia and gestational hypertension as maternal 
BMI increases37. However this also has to be contrasted with the 
increased birth weights of babies born to women with high BMIs.
In the current study we found a remarkably strong association 
between GDF15 concentrations around week 15 of pregnancy 
Figure 2. The relationship between maternal serum GDF15 concentrations around week 15 of pregnancy and pre-pregnancy BMIs. 
(a) A scatter plot of untransformed GDF15 concentrations from around week 15 of pregnancy and pre-pregnancy BMI data from the Cambridge 
Baby Growth Study, (b) a scatter plot of transformed data from the same cohort, (c) a scatter plot of untransformed GDF15 and BMI data from 
the NIPTeR Study and (d) a scatter plot of transformed data from the same study.
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and week 14 hCG levels. Both are major endocrine products 
of the placenta and it is likely that they at least in part reflect 
the functional mass of placenta. Fewer women has hCG meas-
ured in our study which may explain why we did not demon-
strate a relationship of hCG levels and symptoms. Although it 
the most widely implicated hormone thought to stimulate NVP, 
hCG’s link to NVP is inconsistent13 and largely relates to asso-
ciations between the timing of changes in its concentrations and 
NVP symptoms rather than to a known pathogenesis24. Given 
that there is a potential mechanism linking GDF15 concentra-
tions in pregnancy with vomiting38, the results from the present 
study raise the possibility that GDF15 is actually the causal 
factor (or at least one of them) and that reported associations 
between hCG and NVP24 actually reflect GDF15 concentrations 
and bioactivity. These findings require confirmation in other 
studies.
Although we have uniquely shown associations between 
circulating GDF15 concentrations and vomiting in pregnancy, 
pre-pregnancy BMI and circulating hCG levels, this study has a 
number of limitations. Ideally, we would have measured mater-
nal GDF15 concentrations in samples collected at gestational 
age 9 weeks, which is the peak for NVP symptoms39. However, 
many women have not yet presented to maternal health 
services at that stage, and indeed for many women NVP 
represents the first indication of pregnancy. A further limitation 
is that maternal BMI was only available pre-pregnancy although 
weight is unlikely to have changed much during the initial 15 
weeks of pregnancy. Finally and unsurprisingly, reflecting recruit-
ment of the cohort at routine antenatal clinics, cases of HG 
were under-represented. Future case-control study designs are 
therefore needed to test whether our findings can be extrapolated 
to HG.
On the basis of a substantial body of recently emerging data we 
have previously proposed that the role of GDF15 in the adult 
organism is to provide a signal to the brain that the organism is 
engaging in damaging behavior38. Its hindbrain-localized recep-
tor activates a signal which is likely to be aversive and promote 
the future avoidance of this particular behavior. We propose that 
the placenta has evolved to use the GDF15 system to promote 
a state in which the mother is sensitized to other adverse 
stimuli, particularly those that might come from food, in 
order to protect the fetus from exposure to maternal ingestion 
of potential teratogens during the vulnerable stages of organ 
development. In the context of the recently revealed biology 
of GDF15 these data suggest that antagonism of GDF15 may 
have some potential for therapeutic benefit in NVP.
Data availability
Open Science Framework: Data for associations of vomiting 
and antiemetic use in pregnancy with levels of circulating 
GDF15 early in the second trimester: A nested case-control 
study. https://doi.org/10.17605/OSF.IO/5JT3K40.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Data are present from both the Cambridge Baby Growth and 
the NIPTeR Studies, merged from the individual central record 
databases for each study. Anonymized data for the Cam-
bridge Baby Growth study are available to other investigators 
through collaborative agreements, and the co-investigators 
welcome formal or informal proposals and will consider these 
at their bimonthly meetings. Please contact Dr Carlo Acerini 
[cla22@cam.ac.uk]. Concerning NIPTeR study data, please 
contact Dr. Gijs Afink [g.b.afink@amc.uva.nl].
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around week 15 in pregnancy were higher in women who reported vomiting in the second trimester
compared to women who reported no nausea.
It is a well conducted study using data from women  and blood samples from women who took part in well
known, clearly defined prospective studies. The number of women reporting no NVP symptoms is in line
with published data.
This paper is the first to relate GDF15 concentrations to vomiting during pregnancy and as such is of
considerable interest. The aetiology of nausea and vomiting in pregnancy is as yet unknown and so
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from LMP. This means that much information about the NVP symptoms would be retrospective through
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